For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Mesoblast, Inc

USPTO Granted Patents = 31

% Expired Patents = 3.2

CIPO Patents = 7

EPO Patents = 29

Trademarks = 4

Forward Citations = 63

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Silviu Itescu (18 out of 31 patents)

Peter Ghosh (9 out of 23 patents)

Ravi Krishnan (9 out of 14 patents)

4. Stan Gronthos (8 out of 20 patents)

5. Michael David Schuster (5 out of 5 patents)

6. Andrew Christopher William Zannettino (3 out of 5 patents)

7. Andrew Zannettino (3 out of 12 patents)

8. Andrew Zannetino (1 out of 1 patent)

9. Claude Bernard (1 out of 1 patent)

10. Songtao Shi (1 out of 15 patents)

11. John Paul Simmons (1 out of 2 patents)

12. Andrew Christopher Williem Zannettino (1 out of 1 patent)

13. Paul John Simmons (1 out of 1 patent)

14. Paul J Simmons (1 out of 10 patents)

15. Piroska Elizabeth Rakoczy (0 patent)

Core Competencies:

Invertebral Discs

Multipotential Cells

Connective Tissue

Osteoblastic Function

Graft Versus Host Disease

Respiratory Conditions

Rheumatic Disease

Bone Marrow Mononuclear Cells

Pluripotent Cells

Haemopoietic Precursors

Obesity

Pancreatic Dysfunction

31 patents: Sort by Forward Citations

1. 12558382 - Repair and/or reconstruction of invertebral discs (2026-02-24),

2. 12275801 - Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase (2025-04-14),

3. 12220433 - Methods of generating, repairing and/or maintaining connective tissue in vivo (2025-02-11),

4. 11135249 - Methods for increasing osteoblastic function (2021-10-05),

5. 10849932 - Method of treating graft versus host disease (2020-12-01),

6. 10688134 - Methods of treating or preventing respiratory conditions (2020-06-23),

7. 10596199 - Methods of treating or preventing rheumatic disease (2020-03-24),

8. 10544394 - Method of increasing proliferation of bone marrow mononuclear cells expressing STRO1- (2020-01-28),

9. 10421946 - Perivascular mesenchymal precursor cells (2019-09-24),

10. 10220057 - Mesenchymal precursor cell (2019-03-05),

11. 10206951 - Methods of treating multiple sclerosis using STRO-1+ and TNAP+ multipotential cells (2019-02-19),

12. 10159696 - Methods for treating obesity and/or metabolic syndrome (2018-12-25),

13. 10105394 - Method of treating graft versus host disease (2018-10-23),

14. 10028979 - Methods of treating or preventing respiratory conditions (2018-07-24),

15. 9974812 - Methods of treating or preventing rheumatic disease (2018-05-22),

Company Overview

Mesoblast, Inc. is a biotechnology company based in New York, specializing in the development of innovative cellular therapies. The organization focuses on harnessing the power of mesenchymal stem cells to address a range of serious medical conditions, including cardiovascular diseases and orthopedic disorders. Mesoblast is dedicated to advancing regenerative medicine through its proprietary technologies, aiming to improve patient outcomes and transform treatment paradigms in various therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

31 Patents

#280 in New York, NY

#654 in New York

#10,921 in US

#21,238 in the World

New York, NY, United States of America

Mesoblast, Inc

Forward Citations = 63

14 inventors:

Silviu Itescu (18 out of 31 patents)

Peter Ghosh (9 out of 23 patents)

Ravi Krishnan (9 out of 14 patents)

4. Stan Gronthos (8 out of 20 patents)

5. Michael David Schuster (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mesoblast, Inc. Retrieved from https://idiyas.com/company/mesoblast

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…